Overview
Stock Info
Press Releases
Governance
Board of Directors
Management
Documents & Charters
Committee Composition
Financials & Filings
Quarterly Results
Annual Results
SEC Filings
Events
Contact IR
Email Alerts
Investor Contact
Investor FAQs
Management
Chun-Hsien Tsai
Chairman of the Board of Directors
President & Chief Executive Officer
Mr. Chun-Hsien Tsai has served as our Chairman of the Board of Directors, President, Chief Executive Officer, and as a Director since April 15, 2021. From April 15, 2021 until August 11, 2021, he also served as Chief Financial Officer. He concurrently serves as the Chief Executive Officer and Director of Ainos KY, the Chairman of the Board of Directors and Chief Executive Officer of TCNT, and Chief Executive Officer and Director of AI Nose Corporation, a clinical development company and an affiliate of the Company. Mr. Tsai has served as Chief Executive Officer and as a member of the Board of Directors of TCNT since 2012 (and as Chairman and Chief Executive Officer since July 2018), as a Director and President of Ainos KY since 2017, and as a Director and Chief Executive Officer of AI Nose Corporation since 2016. In his capacity as the Chief Executive Officer of TCNT, Mr. Tsai oversaw the completion of the world’s first carbon nanotube reactor. Mr. Tsai also currently serves as a member of the Taiwan Energy Storage Alliance and a member of the China Alternative Energy Association. Mr. Tsai owns more than 150 patents. Mr. Chun-Hsien Tsai is the brother of Mr. Chung-Yi Tsai and Mr. Chun-Jung Tsai. He is also the husband of Ms. Ting-Chuan Lee.
Meng-Lin Sung
Chief Financial Officer
Ms. Meng-Lin Sung has served as our Chief Financial Officer since May 17, 2023. Ms. Sung previously served as Vice President of Finance at Sercomm Corporation since late 2021. Prior to joining Sercomm, she held roles at three of the big four accounting firms — PricewaterhouseCoopers, Ernst & Young, and Deloitte — conducting audits and advising public companies on U.S. GAAP/IFRS and SEC reporting and listing regulations. Ms. Sung has extensive experience guiding publicly-traded healthcare and life science companies through the initial public offering and auditing processes, having previously worked with companies based in the USA and mainland China.
Lawrence K. Lin
Executive VP of Operations
Mr. Lawrence K. Lin has served as Executive Vice President of Operations since August 1, 2021. Prior to his appointment, Mr. Lin provided us with consulting services until August 2021, as the sole member of i2China Management Group, LLC (“i2China”), and served as Executive Advisor to the previous CEO and Chairman of the Company. Mr. Lin provided executive management consulting for Aquahelio Resources, LLC, an unaffiliated company, from 2014 to 2018. Mr. Lin brings more than 30 years of global cross-border strategic management consulting and financial investment experience at leading institutional corporates, such as Andersen Consulting, Salomon Smith Barney, and Credit Suisse First Boston. Mr. Lin has managed investment assets across several geographical locations, including the U.S., China and Taiwan, and advised on many private capital and structured public equity transactions for issuers in real estate, healthcare and consumer sectors. He spent nearly 15 years as an entrepreneur managing an independent Shanghai-based advisory and merchant banking practice where he completed numerous corporate acquisition and investment financing advisory mandates. Mr. Lin has a dual MBA in Finance & International Business from New York University- Stern School of Business.
